PM 01183: Clinical Trials

37 trials of PM 01183, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 recruiting, 9 completed, 4 active not recruiting, 4 withdrawn. 37 Phase 2, 16 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 237Recruiting 12, Completed 9, Active not recruiting 4, Withdrawn 4, Not yet recruiting 3, Unknown 3, Enrolling by invitation 1, Terminated 1
Phase 116Recruiting 5, Unknown 3, Withdrawn 3, Active not recruiting 2, Completed 2, Not yet recruiting 1

Follow PM 01183: new trials by email Literature Review of PM 01183 trials Research Report on PM 01183

Trials (filtered) newest first · largest first

All 37 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingMisty Shields162027-01-012026-10-15
Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer
Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung
Phase 2Not yet recruitingYonsei University692026-11-012026-09-04
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC)
Phase 2Not yet recruitingSichuan University302026-10-312026-05-05
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer
Phase 2RecruitingJazz Pharmaceuticals502026-10-122026-11-06
Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingVA Office of Research and Development1662026-02-232026-03-11
An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing
Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage
Phase 1 / Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1002025-12-312025-08-26
An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment
Lurbinectedin, Radiation Therapy - Small Cell Lung Carcinoma
Phase 2Active not recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences92025-12-312026-06-16
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
ABBV-706, Atezolizumab, Etoposide - Small Cell Lung Cancer
Phase 2RecruitingAbbVie1802025-11-252026-10-27
Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS
Lurbinectedin, Irinotecan - Desmoplastic Small Round Cell Tumor
Phase 2RecruitingItalian Sarcoma Group202025-11-212026-11-03
Patients With High-grade Pancreatic Neuroendocrine Tumors
Lurbinectedin 4 MG Injection [Zepzelca] - Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors
Phase 2Enrolling by invitationNational Cancer Center, Korea462025-09-232025-10-01
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Serplulimab, Lurbinectedin, Carboplatin - Extensive-Stage Small Cell Lung Cancer
Phase 2RecruitingGuangzhou Institute of Respiratory Disease302024-12-012026-06-08
Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas
Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma
Phase 1 / Phase 2WithdrawnUniversity of California, San Francisco2024-10-312024-11-18
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Lurbinectedin, Avelumab - Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
Phase 2RecruitingNational Cancer Institute (NCI)452024-06-132026-11-12
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
Lurbinectedin, Dostarlimab - Endometrial Cancer
Phase 1 / Phase 2WithdrawnVall d'Hebron Institute of Oncology2024-05-012025-04-01
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC)
Phase 1 / Phase 2RecruitingPhanes Therapeutics2032023-09-052026-07-15
Lurbinectedin in FET-Fused Tumors
Lurbinectedin - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor
Phase 1 / Phase 2RecruitingChildren's Hospital of Philadelphia632023-07-272026-09-02
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
Lurbinectedin - Advanced Soft-tissue Sarcoma
Phase 1 / Phase 2UnknownERLINDA M GORDON402023-06-072024-07-05
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Lurbinectedin - Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
Phase 1 / Phase 2RecruitingJazz Pharmaceuticals602023-05-232026-11-05
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin - Metastatic Cancer, Urothelial Carcinoma
Phase 2WithdrawnAdventHealth2023-05-082024-08-01
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Carboplatin, Pemetrexed, Paclitaxel - Lung Cancer, Small-cell Lung Cancer
Phase 2RecruitingFox Chase Cancer Center2802023-02-222026-05-22

Showing 20 of 37. Sign in to see all of them.

Conditions studied

Small Cell Lung Carcinoma (14)  ·  Lung Neoplasms (4)  ·  Sarcoma (4)  ·  Endometrial Neoplasms (3)  ·  Sarcoma, Ewing (3)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Desmoplastic Small Round Cell Tumor (2)  ·  Mesothelioma (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Neuroendocrine Tumors (2)  ·  Adenoma, Islet Cell (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Ovarian Epithelial (1)

Sponsors

PharmaMar (5)  ·  Jazz Pharmaceuticals (3)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)  ·  Massachusetts General Hospital (2)  ·  National Cancer Institute (NCI) (2)  ·  AbbVie (1)  ·  AdventHealth (1)  ·  Antonio Calles Blanco (1)  ·  Children's Hospital of Philadelphia (1)  ·  ERLINDA M GORDON (1)  ·  Fox Chase Cancer Center (1)  ·  Fundacion Oncosur (1)  ·  Guangzhou Institute of Respiratory Disease (1)  ·  HonorHealth Research Institute (1)  ·  Italian Sarcoma Group (1)

Countries

United States (24)  ·  Spain (9)  ·  Italy (5)  ·  China (4)  ·  Germany (3)  ·  South Korea (3)  ·  Switzerland (3)  ·  Belgium (2)  ·  France (2)  ·  Canada (1)  ·  Israel (1)  ·  Japan (1)  ·  Poland (1)  ·  Serbia (1)  ·  Sweden (1)

Top investigators

Anastasios Dimou, MD (1)  ·  Andrea B Apolo, M.D. (1)  ·  Andres Poveda, MD (1)  ·  Anish Thomas, M.D. (1)  ·  Antonio Calles (1)  ·  Erkut Borazanci, MD (1)  ·  Erlinda M Gordon, MD (1)  ·  Federica Grosso, MD (1)  ·  Gregory Cote, M.D. Ph.D (1)  ·  Gregory Cote, MD PhD (1)  ·  Hye Ryun Kim (1)  ·  Jared Weiss, MD (1)  ·  Julia Judd, DO (1)

Results publications

PMID 30240327, PMID 31896519, PMID 32085891, PMID 32224306, PMID 33096421, PMID 33914350, PMID 34739582, PMID 35486638, PMID 35830841, PMID 36037567, PMID 37491889, PMID 37556023, PMID 38964333, PMID 39490738, PMID 39938593, PMID 40116623, PMID 40963055, PMID 41791703, PMID 42081171

NIH funding

2017 (1), 2025 (1)